4560 Horton Street
Grifols is a global healthcare company that since its founding in Barcelona in 1909 has enhanced the health and well-being of people around the world. Our four divisions – Bioscience, Diagnostic, Hospital and Bio Supplies – develop, produce and market innovative solutions and services in more than 100 countries. As pioneers in the field of plasma science, we are one of the largest plasma companies, with a growing network of donation centers worldwide. We develop this plasma into essential medicines used to treat chronic, rare and, at times, life-threatening conditions. As a recognized leader in transfusion medicine, we also offer a comprehensive portfolio of solutions designed to enhance safety from donation through transfusion. We continue to advance our legacy of innovation by supplying tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care. Grifols, with more than 24,000 employees in 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership in the industry.
For more information, please visit grifols.com.
Stock Exchange: NASDAQ
Stock Symbol: GRFS
At Grifols, every employee has an opportunity to make a positive impact on the lives of others, while developing their career at an international forward-thinking company. Join us in shaping the future of healthcare, together.
105 articles with Grifols
The Dow Jones Sustainability Index recognizes Grifols as one of the world's most sustainable companies
Grifols has been recognized among the world's most sustainable companies by the Dow Jones Sustainability Index, the largest global sustainability index and an international benchmark for socially responsible investors.
The integration of Grifols PharmacyKeeper and clinical education resources from TRC Healthcare will help pharmacy leaders by delivering the most current and relevant evidence-based education available
The trial, part of a collaboration with U.S. government agencies including BARDA, the FDA and the NIH, will evaluate the safety, efficacy and tolerability of the anti-SARS-CoV-2 hyperimmune globulin that, if proven safe and effective, could be a potential treatment for COVID-19
Grifols closes the acquisition of Green Cross fractionation plant in Canada and 11 plasma centers in the U.S.
The investment includes a fractionation plant with a 1.5 million-liter annual capacity and two purification plants, making Grifols the only large-scale commercial manufacturer of plasma products in Canada - This transaction highlights Grifols' commitment to supporting countries such as Canada to attain self-sufficiency of essential plasma-derived medicines through
9/10/2020Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
The transaction, which is set to conclude in early 2021, will give Grifols access to Alkahest’s four product candidates.
Grifols to acquire Alkahest to enhance discovery research and development to identify innovative therapies for age-related diseases based upon an understanding of the human plasma proteome
Grifols to acquire remaining stock of Alkahest, Inc. in exchange for a total price of $146 million, on a debt-free basis, bringing its ownership of Alkahest to 100%; the transaction is expected to close in early 2021
ICU Medical Broadens its Non-PVC/Non-DEHP IV Solutions Portfolio by Entering Long-Term U.S. Distribution Agreement with Grifols for Certain Core IV Solution Products
ICU Medical Inc. announced that it has entered into a long-term agreement with Grifols to distribute a full line of non-PVC/non-DEHP IV containers for 0.9% Sodium Chloride Injection, USP to customers in the United States.
Grifols delivers first manufactured batches of its anti-SARS-CoV-2 hyperimmune globulin for clinical trials
- The therapy, which provides passive immunity and could be used for both prevention and treatment, will undergo clinical trials this summer to evaluate its safety and efficacy - This is part of a collaboration agreement with U.S. government entities, including the Food and Drug Administration (FDA), the National Institutes of Health (NIH) and the Biomedical Advanced Research Development Authority (BARDA), among other healthcare agencies - In the past months Grifols has been
Grifols to acquire Green Cross plasma fractionation facility in Montreal and a plasma collection organization in the U.S. for US$460 million
Grifols makes a significant investment to become the only large-scale commercial manufacturer of plasma products in Canada, with a fractionation capacity of 1.5 million liters/year
Amidst the pandemic, the biopharma industry continues to surge ahead. Jobs look plentiful. Check out these companies that have made recent job announcement expansions.
Grifols starts production of its hyperimmune immunoglobulin as a potential passive immune therapy against COVID-19
Grifols continues to lead initiatives to combat COVID-19 with the development of the first specific drug
Biotech Bay, the bustling biotech industry around San Francisco in California, is home to many biopharma companies developing diagnostics, therapies, and vaccines to fight against coronavirus disease 2019 (COVID-19) and the virus that causes it, called SARS-CoV-2.
- ART enables greater workflow efficiency and lean sample management, supporting laboratories' path towards total automation - The Procleix Panther System featuring ART improves system usability, increases operator walk-away time, and allows laboratories to select efficient configurations for current or future blood donor screening automation needs - The Grifols ART program is a cross-platform, long-term research and development initiative to enable ongoing advancements in la
- Now available in a third vial size (3-mL - 900-IU), HyperRAB, the only high-potency formulation of rabies immunoglobulin, gives healthcare professionals more convenient dosing options, reduces storage space and minimizes unnecessary waste - HyperRAB is presently the number one prescribed rabies immunoglobulin in the U.S., with over 1 billion international units administered to more than 1 million patients over 45 years - Grifols continues to expand its leadership in disease
Grifols, S.A. announced that it has filed its 2019 Annual Report on Form 20-F with the United States Securities and Exchange Commission on April 6, 2020.
Aradigm Corporation announced on March 30, 2020, the Bankruptcy Court entered an order approving the sale by Aradigm Corporation to Grifols, S.A. of the Company's assets and intellectual property that pertain to Lipoquin, Free Ciprofloxacin, Apulmiq and any derivatives thereof.
Grifols Announces Formal Collaboration with US Government to Produce the First Treatment Specifically Targeting COVID-19
Grifols announces that it has entered into a formal collaboration with the US Biomedical Advanced Research Development Authority, the FDA and other Federal public health agencies to collect plasma from convalescent COVID-19 patients, process this specific plasma into a hyperimmune globulin and support the necessary preclinical and clinical studies to determine if anti-SARS-CoV-2 hyperimmune globulin therapy can successfully be used to treat COVID-19 disease.
Feb. 21, 2020 13:00 UTC NEWARK, Calif.--( BUSINESS WIRE )-- Aradigm Corporation (OTC PINK: ARDM) (“Aradigm” or the “Company”) today announced that the Company has entered into an Asset Purchase Agreement pursuant to which Grifols, S.A. (the “Buyer”) will acquire the Company’s assets and intellectual property that pertain to Lipoquin, Free Ciprofloxacin, Apulmiq and any derivatives thereof. The sale is subject to the approval of the Bankruptcy Court, and is subject to the results o
- Fourth straight year in which the prestigious healthcare research firm selects PharmacyKeeper Verification as the No. 1 Category Leader for Intravenous (IV) Workflow Management - PharmacyKeeper Verification is a strategic part of Grifols' inclusiv® portfolio, offering integrated technology, software and service solutions dedicated to advancing quality and safety in pharmacy operations